Detalhe da pesquisa
1.
EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models.
Neuro Oncol
; 2024 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38507464
2.
Perspectives on Treatment of Alzheimer's Disease: A Closer Look into EphB2 Depletion.
J Neurosci
; 37(47): 11296-11297, 2017 11 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29167398
3.
Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo.
Neuro Oncol
; 22(4): 493-504, 2020 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31883012
4.
Targeting metabolic plasticity in glioma stem cells in vitro and in vivo through specific inhibition of c-Src by TAT-Cx43266-283.
EBioMedicine
; 62: 103134, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33254027
5.
Erratum to "Targeting metabolic plasticity in glioma stem cells in vitro and in vivo through specific inhibition of c-Src by TAT-Cx43266-283" [EBioMedicine 62, December 2020] DOI: https://doi.org/10.1016/j.ebiom.2020.103134.
EBioMedicine
; 74: 103752, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34911027
6.
Erratum to 'Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo'.
Neuro Oncol
; 23(8): 1414, 2021 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32515482